Innate immune pathways recruited by MF59 adjuvant

The innate immune pathways recruited by the MF59 adjuvant represent a complex network of cellular and molecular events that enhance the efficacy of vaccines (O'Hagan et al., 2012). MF59, a squalene-based oil-in-water emulsion, does not target a single receptor but rather induces a local immunocompetent environment characterized by the secretion of chemokines like CCL2, CCL3, and CXCL8 (Seubert et al., 2008). This leads to the rapid recruitment of various innate immune cells, including monocytes, macrophages, and granulocytes, to the site of injection (Vono et al., 2013). A key molecular component of this response is the MyD88 adapter protein, which mediates downstream signaling independently of traditional Toll-like receptors (TLRs) (Ellebedy et al., 2011). Additionally, MF59 promotes the release of endogenous danger signals such as ATP and may activate the NLRP3 inflammasome, further driving the maturation of antigen-presenting cells and the subsequent adaptive immune response (Tritto et al., 2009). This multifaceted recruitment of innate pathways is crucial for the potent adjuvant activity of MF59 in seasonal and pandemic influenza vaccines (O'Hagan et al., 2012).

Other names

MF59-mediated innate immune activationMF59 mechanism of actionSqualene-based adjuvant signalingMF59-induced immunocompetent environment

MF59 acts as an adjuvant by creating a local immunocompetent environment at the injection site, inducing the release of chemokines (e.g., CCL2, CXCL8), and recruiting immune cells such as monocytes and dendritic cells (O'Hagan et al., 2012). It activates the MyD88-dependent signaling pathway independently of Toll-like receptors (TLRs) and may involve the activation of the NLRP3 inflammasome and the release of endogenous danger signals like ATP (Ellebedy et al., 2011).